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Wednesday, February 24, 2010 755athe residues are close to each other in closed, open or inactivated states. With
this technique, we have detected and analyzed molecular movements within the
voltage-sensor domain, between the voltage sensor and the pore domain, and
within the pore domain.Minisymposium 4: New Chemical Modulators by
Rational Design
3927-MiniSymp
Optimizing Ligand-Protein Interactions Via Silcs: Site Identification by
Ligand Competitive Saturation
Alexander MacKerell.
Univ Maryland, Baltimore, MD, USA.
Fragment-based methods for drug optimization have great potential; however,
time, expense and sensitivity considerations associated with NMR and x-ray
crystallographic based methods limit their applicability. As an alternative we
have developed a computational approach, SILCS: Site Identification by
Ligand Competitive Saturation, that uses explicit solvent all-atom molecular
dynamics to identify binding sites on protein surfaces for functional groups.
Information from the SILCS approach may then be combined with structural
information on an inhibitor-protein complex to facilitate modification of the
ligand to improve its binding affinity. An overview of SILCS and its application
to inhibitor-ligand optimization will be presented.
3928-MiniSymp
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific
Drug Binding
Stephen G. Aller.
Univ. Alabama at Birmingham, Birmingham, AL, USA.
P-glycoprotein (Pgp) detoxifies cells by exporting hundreds of chemically unre-
lated toxins but causesmultidrug resistance in the treatment of cancers. Substrate
promiscuity is a hallmarkof Pgp activity, thus a structural descriptionof polyspe-
cific drug-binding is vital for the rational design of anticancer drugs and MDR
inhibitors. The x-ray structure of apo-Pgp at 3.8 A˚ reveals an internal cavity of
~6,000 A˚3 with a 30 A˚ separation of the two nucleotide binding domains
(NBD). Two additional Pgp structures with novel cyclic peptide inhibitors dem-
onstrate distinct drug binding sites in the internal cavity capable of stereo-selec-
tivity that is based on hydrophobic and aromatic interactions. Apo- and drug-
bound Pgp structures have portals open to the cytoplasm and the inner leaflet
of the lipid bilayer for drug entry. The inward-facing conformation represents
an initial stage of the transport cycle that is competent for drug binding.
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Chemical Synthesis of a Highly Selective Probe of the Renal Outer
Medullary Potassium Channel (ROMK)
Jerod S. Denton, Brian A. Chauder, Rishin Kadakia, Eric S. Dawson,
Craig W. Lindsley, C. David Weaver, Gautam Bhave.
Vanderbilt University School of Medicine, Nashville, TN, USA.
The renal outer medullary potassium channel, ROMK, critically regulates salt
and water balance and may be a drug target for a novel class of diuretic. How-
ever, the molecular pharmacology of the inward rectifier potassium channel
family is virtually undeveloped, precluding assessment of ROMK’s therapeutic
potential. We therefore performed a high-throughput screen of approximately
225,000 small molecules for modulators of ROMK function, from which sev-
eral novel antagonists were identified. One compound, termed VU590, inhibits
ROMK with a half-inhibition concentration (IC50) of 300 nM, has no effect on
Kir2.1 or Kir4.1, but inhibits Kir7.1 at low micromolar concentrations. Two
structurally related compounds were identified in the screen, but were found
to be comparatively weak ROMK inhibitors. Using a molecular mechanics-
based knowledge of VU590, medicinal chemistry was employed to improve
the potency of one compound 33-fold (IC50 from 8 mM to 240 nM). This novel
probe, termed VU591, is highly selective for ROMK over Kir2.1, Kir2.3,
Kir4.1, Kir6.2/SUR1B, Kir7.1 and a panel of more than 65 other potential
off-targets, including voltage-gated sodium and calcium channels and hERG.
Functional studies suggest the VU591 binding site is located in the cytoplasmic
pore of ROMK. VU591 will be instrumental in mapping the location and topo-
graphical features of this selective binding site and could pave the way for an-
imal studies assessing the therapeutic potential of ROMK.
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Gold Nanoparticles as a Platform for Designing Protein-Protein Interac-
tion Inhibitors: Application to Ubiquitin-Like Modifications
Yang Su, Angela Perkins, Yi-Jia Li, Yuelong Ma, David Horne, Yuan Chen.
Beckman Research Institute of the City of Hope, Duarte, CA, USA.Inhibitors of non-covalent protein-protein interactions hold much promise as
useful probes to our understanding of human biology and disease mechanisms,
as well as leads for developing new therapies. Developing such inhibitors, how-
ever, continues be a significant challenge. Protein-protein interactions mediated
by ubiquitin-like (Ubl) modifications are among the most important signalling
and regulatory mechanisms that control nearly every aspect of cellular func-
tions. A unique feature of these post-translational modifications is the forma-
tion of poly-Ubl chains; however, strategies to target these poly-Ubl chain
modified proteins are lacking. In this study, we show that gold nanparticles
(AuNPs) conjugated with small molecule inhibitors can selectively target
such poly-Ubl chains. Virtual ligand screening was carried out to identify small
molecule mimmetics of the Small Ubiquitin-like MOdifier (SUMO) interaction
motif in order to inhibit SUMO-mediated down-stream effects. Virtual ligand
screening was based on the NMR structure of SUMO in complex with a peptide
containing the SUMO-interaction motif. Interactions of the hit compounds with
SUMO were investigated by NMR methods. One of the hits was modified for
conjugation to an AuNP by adding a thiol tail. While the individual compounds
do not have high affinity for SUMO (having Kd of 2 mM), conjugation of ap-
proximately 100 compounds to one AuNP allows for multi-valent interactions
between AuNP and multiple SUMO proteins in a poly-SUMO chain; thus effi-
ciently inhibits poly-SUMO-chain-mediated protein-protein interactions. This
study demonstrates a viable approach to creating highly effective inhibitors
by using AuNPs as a platform for multivalent interactions. This is the first
application of AuNP for inhibiting Ubl modifications and provides a novel ap-
proach to specifically and effectively address such types of Ubl modifications
for future research and therapeutic applications.
3931-MiniSymp
New Approaches to Anti-Infective and Anti-Cancer Therapeutics
Targeting Metalloproteins
Eric Oldfield.
university of illinois at urbana, urbana, IL, USA.
I will give an account of recent progress in the development of novel anti-in-
fectives targeting isoprenoid biosynthesis. Topics to be covered include: carot-
enoid biosynthesis as a target in staph and malaria; novel inhibitors of bacterial
farnesyl and undecaprenyl diphosphate synthase; and the mechanism of action
of the Fe4S4 cluster-containing proteins, GcpE (IspG) and LytB (IspH). We
have investigated the mechanism of action and inhibition of Aquifex aeolicus
LytB using a combination of site-directed mutagenesis (KM, Vmax), EPR and
1H, 2H, 13C, 31P and 57Fe-ENDOR. The EPR and ENDOR results support
formation of an initial pi/sigma ‘‘metallacycle’’ complex similar to that ob-
served previously with allyl alcohol bound to a nitrogenase FeMo cofactor.
The complex is poised to interact with the E126 CO2H group, resulting in
loss of H2O and formation of eta1 and/or eta3-allyl complexes. The IPP and
DMAPP products are then formed in a second Hþ/e- reduction step. We also
report that alkyne diphosphates are inhibitors of IspH and likewise form pi
or pi/sigma metallacycle complexes, as evidenced by 1H, 2H, and 13C
ENDOR. I will also give an update on the mechanism of action of GcpE,
and the discovery of potent, mechanism-based, inhibitors of this enzyme.Platform BF: Cardiac Muscle II
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Proteomics of the Human Cardiac Intercalated Disc: A More Complex
Multi-Functional Structure than was Previously Thought
Cristobal G. dos Remedios1, Colleen Estigoy2, Darryl Cameron3,
Joshua W.K. Ho3, Benjamin Herbert4, Matthew Padula4, Russel Pickford5,
Michael Guilhaus5, Jacob Odeberg6, Fredrik Ponten7.
1University of Sydney, Sydney, Australia, 2Bosch Institute (F13), The
University of Sydney, Sydney, Australia, 3The University of Sydney, Sydney,
Australia, 4University of Technology Sydney, Sydney, Australia, 5University
of New South Wales, Kensington, Australia, 6Royal Institute of Technology,
Stockholm, Sweden, 7University of Uppsala, Uppsala, Sweden.
The intercalated disc (ICD) of cardiac muscle joins one cardiomyocyte to sev-
eral others. It transmits contractile force between these heart muscle cells, but it
also must allow action potentials, ions and even small molecules to cross the
junctions, it contains multiple receptors, and must permit the cardiomyocytes
to grow. The literature contains 142 proteins in mammalian hearts that were
identified using a wide range of techniques. Here we employ two technologies
that nearly double this number. We use Fourier transform mass spectrometry to
identify 84 proteins based on an analysis of their tryptic peptides using purified
(but not pure) ICDs from human left ventricles from four non-failing hearts,
only about half of which (43) were previously known. We then explore the
Human Proteome Atlas (HPA) database to identify 162 ICD proteins using
